Table 2.
Prevalence of anxiety.
| Study | Country | Population | Sample size | Period of data collection | Instrument | Prevalence |
|---|---|---|---|---|---|---|
| Abu-Snieneh et al. (2020)13 | KSA | Nurses | 1265 | End of April 2020. Middle of June 2020 | GAD-7 | Mild: 31.2% Moderate: 9.7% Severe: 8.8% Moderate to severe: 18.5% |
| AlAmmari et al. (2021)23 | KSA | HCWs | 720 | 27 April 2020–4 May 2020 | GAD-7 | Mild: 28.47% Moderate: 12.77% Severe: 8.33% Moderate to severe: 21.1% |
| Alamri et al. (2020)24 | KSA | General population (including HCWs) | 542 (HCWs only) | 10 May 2020–16 May 2020 | DASS-21 | 20.1% (cut-off 21) |
| AlAteeq et al. (2020)26 | KSA | HCWs | 502 | March 2020 | GAD-7 | Mild: 25.1% Moderate: 11% Severe: 15.3% Moderate to severe: 26.3% |
| Alenazi et al. (2020)28 | KSA | HCWs | 4920 | 15 May 2020–18 May 2020 | Dispositional cancer worry scale | Low: 31.5% Medium: 36.1% High: 32.3% Medium to high: 68.3% |
| AlMahyijari et al. (2020)31 | Oman | Nurses and physicians | 150 | – | GAD-7 | 28.67% |
| AlMaqbali et al. (2021)32 | Oman | Nurses | 1130 | 7 August 2020–17 August 2020 | HADS | 44.2% |
| Almater et al. (2020)29 | KSA | Ophthalmologists | 107 | 28 March 2020–4 April 2020 | GAD-7 | Mild: 25.2% Moderate: 15.9% Severe: 5.6% Moderate to severe: 21.5% |
| Alsairafi et al. (2021)37 | Kuwait | HCWs and health students | 559 (HCWs only) | May 2020–July 2020 | GAD-7 | Mild: 19.5% Moderate: 43.1% Severe: 37.4% Moderate to severe: 80.5% |
| Alsaywid et al. (2020)15 | KSA | Residents and fellows | 1528 | – | GAD-7 | Mild: 26.7% Moderate: 24.5% Severe: 35.6% Moderate to severe: 60.1% |
| Alshekaili et al. (2020)33 | Oman | HCWs | 1139 | 8 April 2020–17 April 2020 | DASS-21 | 34.1% |
| Alzaid et al. (2020)17 | KSA | HCWs | 441 | GAD-7 | Mild: 27% Moderate: 13.2% Severe: 7.9% Moderate to severe: 21.1% |
|
| Arafa et al. (2020)40 | KSA and Egypt | HCWs | 151 (KSA only) | 14 April 2020–24 April 2020 | DASS-21 | Mild to moderate: 26.5% Severe to very severe: 15.2% Mild to very severe: 41.7% |
| Badahdah et al. (2020)34 | Oman | Physicians and nurses | 509 | 1st two weeks of April 2020 | GAD-7 | Mild: 38.7% Moderate: 17.7% Severe: 8.3% Moderate to severe: 26% |
| Balay-Odao et al. (2021)18 | KSA | nurses | 281 | April 2020–June 2020 | DASS-21 | Mild: 6.8% Moderate: 37.4% Severe: 12.1% Extremely severe: 7.5% Mild to extremely severe: 57% |
| Burhamah et al. (2020)38 | Kuwait | General population (including HCWs) | 282 (HCWs only) | 25 May 2020–30 May 2020 | GAD-7 | 34% |
| Jahan et al. (2021)35 | Oman | Physicians and nurses in PHCs | 327 | – | DASS-21 | Mild: 13.4% Moderate: 27.1% Severe: 10.3% Extremely severe: 10.9% Mild to extremely severe: 61.7% |
| Joseph et al. (2020)19 | KSA | General population (including HCWs) | 110 (HCWs only) | 12 April 2020–10 May 2020 | PHQ-4 | Moderate to severe (combined anxiety–depression): 20% |
| Khamis et al. (2020)36 | Oman | Female physicians and nurses | 402 | April 2020 (first 2 weeks) | GAD-7 | Mild: 39.6% Moderate: 18.9% Severe: 8.9% Moderate to severe: 27.8% |
| Shalaby et al. (2021)20 | KSA | HCWs in tertiary hospitals | 1182 | 1 June 2020–31 July 2020 | GAD-7 | Moderate: 9% Moderately severe: 48% Severe: 33% Moderately severe–severe: 81% |
| Surrati et al. (2020)21 | KSA | HCWs | 118 | April 2020 | HADS | Borderline: 21.2% Abnormal: 35.6% Total: 56.8% |
| Temsah et al. (2020)22 | KSA | HCWs | 582 | 5 February 2020–16 February 2020 | GAD-7 | Mild: 20.8% Moderate: 8.1% Severe: 2.9% Moderate to severe: 11% |